Australian company Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease. …
Dimerix raises $20 million to continue and expand late-stage clinical trial of DMX-200
March 12, 2024 Australian Biotech
Latest Video
New Stories
-
Nurse prescribing reform set to expand access to PBS subsidised medicines
July 3, 2026 - - Latest News -
Cartherics emerges as Asia Pacific leader in off-the-shelf immune cell therapy
July 2, 2026 - - Australian Biotech -
Minister looks to be sending a very clear message about these therapies and the PBS
July 2, 2026 - - Latest News -
The end-game of strong-arming companies over prices at the expense of patients and process
July 2, 2026 - - Latest News -
Commercial outsourcing emerges as a strategic option to patient access
July 1, 2026 - - Latest News -
The minister is following a tried and tested process, but what is the risk in this new world?
July 1, 2026 - - Latest News -
Patient alarm over the potential loss of subsidised access to MS medicines
July 1, 2026 - - Latest News